Nasdaq Arwr News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) has been given an average recommendation of “Moderate Buy” by the thirteen analysts that are presently covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target […]

E Fund Management Co. Ltd. grew its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 20.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,293 shares of the biotechnology company’s stock after purchasing an additional 2,647 shares during the […]

E Fund Management Co. Ltd. boosted its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 20.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,293 shares of the biotechnology company’s stock after acquiring an additional 2,647 shares during the period. E Fund Management […]

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 7,720,000 shares, a decrease of 13.0% from the January 15th total of 8,870,000 shares. Based on an average daily volume of 1,550,000 shares, […]

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) had its target price hoisted by analysts at Citigroup from $33.00 to $34.00 in a report released on Wednesday, Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. Citigroup’s price objective would suggest a potential upside of 8.35% from the stock’s previous close. […]